Longer follow-up continues to reveal no increased risk of cancer with the use of recombinant human bone morphogenetic protein in spine fusion |
| |
| Affiliation: | 1. Department of Evidence Based Medicine, Spectrum Research, Inc., PO Box 88998, Steilacoom, WA 98388, USA;2. Swedish Medical Center, Swedish Neuroscience Institute, Jefferson Tower, 1600 E. Jefferson St, Seattle, WA 98122, USA;3. Department of Orthopedics, Spine Surgery Service, Georgia Regents University, 1120 15th St, Augusta, GA 30912, USA;4. Department of Orthopedic Surgery and Rehabilitation, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216, USA;1. Spine Unit, Department of Orthopedic Surgery, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark;2. Combined Neurosurgical and Orthopedic Spine Program, Vancouver General Hospital, University of British Columbia, Floor 6, Blusson Spinal Cord Center, 818 West 10th Ave, Vancouver, British Columbia, Canada V5Z 1M9;3. Department of Orthopedics and Scoliosis Surgery, Texas Children''s Hospital & Baylor College of Medicine, 6621 Fannin St, Houston, TX 77030, USA;1. Department of Physical Medicine and Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA;2. Institute for Healthcare Policy and Innovation, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA;3. Department of Obstetrics and Gynecology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA;4. Department of Emergency Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA;5. Department of Surgery, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA;1. Department of Orthopedic Surgery, NYU Langone Orthopedic Hospital, New York, NY, USA;2. Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, USA;3. Department of Neurosurgery, University of Virginia Medical Center, Charlottesville, VA, USA;4. Department of Orthopaedic Surgery, Warren Alpert School of Medicine, Brown University, Providence, RI, USA;5. Department of Orthopedic Surgery, Rocky Mountain Scoliosis and Spine Center, Denver, Colorado, USA;6. Deparment of Orthopedic Surgery, Hospital for Special Surgery, New York, NY, USA;7. Department of Neurosurgery, University of South Florida, Tampa, FL, USA;8. Division of Orthopaedic Surgery, Scripps Clinic, La Jolla, CA, USA;9. Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;10. Department of Orthopaedic Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA;11. Department of Orthopaedic Surgery, Swedish Neuroscience Institute, Seattle, WA, USA;12. Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA;13. Rocky Mountain Scoliosis and Spine, Denver, CO, USA |
| |
| Abstract: | BACKGROUND CONTEXTLarge observational studies on potential oncogenic effects of recombinant human bone morphogenetic protein (rhBMP) in spine fusion surgery are limited by relatively short follow-up times.PURPOSETo study the possible association between rhBMP and cancer risk in a long-term follow-up study.STUDY DESIGNA retrospective cohort study using a combination of the Washington State Comprehensive Hospital Abstract Reporting System, the Washington State Cancer Registry, State of Washington death certificates, and the Washington State Department of Licensing.PATIENT SAMPLEParticipants were adults age ≥21 years who underwent spine fusion surgery enhanced by rhBMP for degenerative spine disease between January 1, 2002 and December 31, 2010. A comparison group matching each patient receiving rhBMP with three patients not receiving rhBMP was created using the indicators of age, sex, and year of treatment. We excluded patients receiving spine fusion for vertebral fractures or infection, and those with a diagnosis of cancer before or at the index procedure.OUTCOME MEASURESThe primary outcome was the first diagnosis of any cancer as identified in the records of the state cancer registry or death certificate through the end of 2015.METHODSWe compared cancer risk between those receiving spine fusion with and without rhBMP using survival analysis. We calculated incidence rates (hazards) by computing the ratio of the number of events and total time at risk. Unadjusted hazard ratios (HR) and adjusted HR (aHR) and their respective 95% confidence intervals (CI) were calculated assuming a Cox proportional hazard regression model. We adjusted the model to include the site of surgery (lumbar vs. cervical) as a covariate as this differed in frequency between the two treatment groups. To assess whether rhBMP adversely affects the progression of cancer, we compared mortality between rhBMP users and nonusers in those who developed cancer. Research support toward this study was received from Medtronic Sofamor Danek USA. The investigators alone, and not Medtronic, were solely responsible for the design, conduct, analysis, and reporting of this study.RESULTSWe included 16,914 patients who had spine fusion, of whom 4,246 received rhBMP. During the study period, 1,342 patients were diagnosed with some form of cancer. The incidence rate was similar between the two groups: 11.2 per 1,000 person years in the rhBMP group and 10.4 per 1,000 person years in the non-rhBMP group, with an aHR of 0.96; 95% CI, 0.85 to 1.10. Similarly, rhBMP use was not associated with an increased risk of commonly occurring individual cancer types, nor with cancer specific mortality after a cancer diagnosis, aHR, 0.92; 95% CI, 0.69 to 1.22.CONCLUSIONSLong-term follow-up confirms previous findings that rhBMP application treated with elective spinal fusion did not result in an increased cancer risk in a large population of US adults. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
